Does State Medicaid Cover Lantus (Insulin Glargine)?

How Medicaid Decides Whether to Cover Lantus

Medicaid coverage for Lantus is not set by a single federal rule. Each state designs its own Preferred Drug List (PDL) within the broad framework of federal Medicaid law, specifically 42 U.S.C. § 1396r-8, which requires states to cover all FDA-approved drugs from manufacturers who sign a rebate agreement but allows states to manage utilization through prior authorization and preferred-drug tiers [1]. The Centers for Medicare and Medicaid Services (CMS) publishes the governing guidance at CMS.gov, but day-to-day formulary decisions belong to each state's Medicaid agency or its contracted managed-care organizations (MCOs).

Lantus received FDA approval in April 2000 for once-daily subcutaneous injection in adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes [2]. Because insulin glargine has been on the market for more than two decades and because basal insulin is considered a cornerstone of diabetes management per the American Diabetes Association's Standards of Care [3], coverage is broad. The challenge is not whether a state covers insulin glargine at all, but which specific product it prefers, at what tier, and under what conditions.

States negotiate supplemental rebates with manufacturers. A state that secures a larger rebate from Sanofi (Lantus) will place Lantus on its preferred tier; one that secures a better rebate from Eli Lilly (Basaglar) or Viatris/Biocon (Semglee) may prefer the biosimilar instead. The FDA has designated Semglee as the first interchangeable biosimilar to Lantus, meaning a pharmacist can substitute it without a new prescription in states that permit interchangeable substitution [4]. This single regulatory fact reshapes coverage decisions in dozens of states.

The ORIGIN trial (N=12,537, median follow-up 6.2 years) published in the New England Journal of Medicine in 2012 demonstrated that insulin glargine targeting fasting glucose below 95 mg/dL did not increase cardiovascular events compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11, P<0.001 for non-inferiority) [5]. That cardiovascular safety signal helped cement basal insulin's place in clinical guidelines and, by extension, in state formulary decisions.

Prior Authorization: What Medicaid Plans Actually Require

Prior authorization (PA) for Lantus on state Medicaid is common, though the specific criteria differ by state. Most PA policies require one or more of the following: a confirmed diagnosis of T1D or T2D documented in the medical record, a prescribing clinician's attestation that basal insulin is medically necessary, HbA1c above a threshold (often 7.5% or 8.0%), and in some states, evidence that a less expensive basal insulin was tried first.

PA requests are submitted through the state Medicaid agency's online portal or via fax to the MCO. Turnaround times vary: federal Medicaid managed-care rules under 42 C.F.R. § 438.210 require standard PA decisions within 14 calendar days and urgent decisions within 72 hours [6]. Many states have adopted shorter timelines. California Medi-Cal, for example, targets 72 hours for standard non-urgent PA and 24 hours for urgent requests under its 2023 MCO contract standards.

PA denials for Lantus most commonly cite one of three reasons: the prescriber did not document that the patient failed a preferred basal insulin first, the diagnosis code submitted did not match the covered indication, or the quantity requested exceeded the allowed days' supply. Each reason has a straightforward remedy, which is why working with the prescriber's office before submission, not after denial, saves time.

The American Diabetes Association's 2024 Standards of Care in Diabetes state that "insulin therapy is necessary for all people with type 1 diabetes and may be necessary for many people with type 2 diabetes" [3]. A PA letter that quotes this guideline directly, alongside the patient's HbA1c and treatment history, is materially stronger than a generic medical-necessity statement.

Step Therapy: Which States Require It and How to Get Past It

Step therapy means the plan requires trial of a preferred drug before it will authorize the requested drug. For basal insulin, step therapy typically means the patient must try NPH insulin (human isophane insulin) or insulin detemir (Levemir) before Lantus will be approved. NPH costs less per unit but requires twice-daily dosing in many patients and carries a higher risk of nocturnal hypoglycemia compared with insulin glargine [7].

A 2005 meta-analysis published in the Annals of Internal Medicine (N=2,304 patients across six randomized trials) found that insulin glargine reduced nocturnal hypoglycemia rates by approximately 48% relative to NPH in patients with type 2 diabetes [7]. When a patient has a documented history of hypoglycemia on NPH, that trial data, combined with chart notes showing hypoglycemic episodes, is typically sufficient to satisfy step-therapy requirements.

States with step-therapy laws, currently more than 30 states have enacted some form of step-therapy reform legislation, are required to provide an exception process. The exception must be granted when step therapy is contraindicated, when the patient has already tried and failed the required drug, or when the required drug would cause clinically significant harm [8]. Clinicians can access the specific exception criteria for a given state through the National Alliance of Mental Illness (NAMI) step-therapy tracker or the state Medicaid agency website.

For patients with type 1 diabetes, step therapy through NPH is almost never clinically appropriate. T1D patients require precise basal-bolus titration, and the variable absorption kinetics of NPH introduce unpredictable glucose excursions. Documenting this risk in a step-therapy exception request, citing the patient's T1D diagnosis and any prior hypoglycemia, typically results in an exception within the standard PA timeframe.

The HealthRX Medicaid PA Decision Framework for Insulin Glargine (reviewed by our medical team) organizes the required documentation into four tiers: (1) diagnosis confirmation with ICD-10 code (E10.xx for T1D, E11.xx for T2D), (2) HbA1c within the prior 90 days, (3) treatment history showing current regimen and any prior basal insulin trials, and (4) clinical justification for glargine specifically, citing nocturnal hypoglycemia risk, dosing convenience, or biosimilar unavailability. Submitting all four tiers in the initial PA request reduces the need for peer-to-peer review in the majority of cases based on our clinical team's experience managing prior authorizations across multiple state Medicaid programs.

Formulary Tiers and Cost-Sharing for Lantus

On state Medicaid formularies, drugs are typically divided into preferred (lower copay or no cost-sharing) and non-preferred (higher cost-sharing or subject to PA) tiers. Because many states now prefer biosimilar insulin glargine products, Lantus (the brand-name Sanofi product) may sit on a non-preferred tier even when it is covered. The biosimilar Semglee, designated interchangeable by the FDA in July 2021 [4], is available for approximately $99 per month list price compared with Lantus at approximately $340 per month [9].

Federal law requires that Medicaid cost-sharing for insulin be nominal. The Inflation Reduction Act of 2022 capped insulin cost-sharing for Medicare beneficiaries at $35 per month, but that cap does not automatically apply to Medicaid [10]. Most state Medicaid programs set copays for preferred insulins at $0 to $4 per prescription under the nominal cost-sharing rules at 42 U.S.C. § 1396o. Non-preferred tiers may carry copays of $8 to $20, though cost-sharing is waived entirely for beneficiaries below certain income thresholds.

A 2022 analysis published in JAMA Internal Medicine examined insulin affordability across payer types and found that Medicaid enrollees had the lowest out-of-pocket costs for insulin among all insurance categories, with a mean of $2.94 per 30-day supply, compared with $34.22 for commercially insured patients [11]. The practical implication is that once coverage is confirmed, Medicaid beneficiaries pay very little. The challenge is obtaining that coverage confirmation.

Biosimilar Insulin Glargine: Semglee, Basaglar, and Rezvoglar

Three biosimilar or follow-on insulin glargine products are available in the United States. Basaglar (Eli Lilly) was approved as a follow-on biological product in December 2015 [12]. Semglee (Viatris/Biocon) received full biosimilar approval and interchangeability designation in July 2021 [4]. Rezvoglar (Eli Lilly) received interchangeability designation in December 2022 [13].

State Medicaid programs have been moving these biosimilars to preferred status because they generate larger supplemental rebates. In practice, a pharmacist dispensing a Semglee or Rezvoglar prescription is substituting an interchangeable product, meaning the clinical outcome data are directly transferable. The FDA's interchangeability standard requires that the biosimilar produce the same clinical result as the reference product in any given patient [4].

If your prescriber writes specifically for Lantus and the pharmacy substitutes Semglee, the substitution is legally permitted in states that allow interchangeable substitution. The prescriber can prevent substitution by writing "dispense as written" on the prescription, though this may trigger a non-preferred PA process. Discussing this decision with the prescriber before the prescription is written avoids delays at the pharmacy.

The clinical pharmacology of all three interchangeable products is the same. Insulin glargine in any formulation has a flat, peakless action profile with a duration of approximately 24 hours, contrasting with NPH's pronounced peak at 4 to 8 hours post-injection [2]. This pharmacokinetic profile is what drives the nocturnal hypoglycemia advantage documented in clinical trials.

Lantus for Type 1 vs. Type 2 Diabetes on Medicaid

Coverage criteria sometimes differ by indication. For type 1 diabetes, Medicaid coverage of basal insulin is effectively universal. T1D requires exogenous insulin for survival, and denying basal insulin coverage for a T1D patient would constitute a failure to provide medically necessary care under federal Medicaid law. The ADA's 2024 Standards of Care are explicit: "All people with type 1 diabetes require insulin therapy" [3].

For type 2 diabetes, the coverage pathway is wider but the PA criteria are sometimes more stringent. Some states require documentation that the patient has failed oral antidiabetic therapy (typically metformin plus at least one additional agent) before approving basal insulin. This mirrors clinical guidelines that recommend starting with lifestyle modification and oral agents before initiating insulin in most T2D patients, though the ADA notes that patients with HbA1c above 10% or with symptoms of hyperglycemia may benefit from early insulin initiation [3].

The ORIGIN trial specifically enrolled patients with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early T2D) rather than established T1D, making it the primary long-term safety dataset for basal insulin glargine in the T2D and prediabetes population [5]. A 6.2-year median follow-up with no increase in cardiovascular events and no increase in cancer rates (a concern raised by earlier observational data) strengthened guideline support for long-term insulin glargine use in T2D.

How to Appeal a Medicaid Denial of Lantus

Every state Medicaid program is required by federal law to offer a fair-hearing process for adverse coverage decisions [6]. When Lantus is denied, the enrollee receives a Notice of Action that must include the reason for denial, the rule or policy cited, and instructions for requesting a hearing. The deadline to request a hearing is typically 90 days from the date of the notice, though some states set shorter windows.

The appeal process has two stages in most states. The first stage is an internal appeal or reconsideration by the MCO or state agency. The second stage is an external fair hearing before an administrative law judge. If the patient needs Lantus while the appeal is pending and was previously receiving it, federal law may require the plan to continue coverage during the appeal under the "continuation of benefits" rule at 42 C.F.R. § 438.420 [6].

To build a strong appeal, gather the following: the denial notice, the prescriber's letter of medical necessity referencing the ADA 2024 Standards of Care, HbA1c results from the past 90 days, records of any hypoglycemic episodes on alternative basal insulins, and the specific step-therapy exception criteria from the state's published policy. A peer-to-peer call between the prescriber and the plan's medical director resolves many denials before a formal hearing is necessary.

A 2019 study in Health Affairs analyzed Medicaid managed-care appeals and found that beneficiaries who submitted complete clinical documentation at the initial appeal stage were substantially more likely to have denials overturned than those who submitted only the prescriber's signature page [14]. Completeness of documentation, not the merits of the request alone, drove outcomes.

Can You Use the Manufacturer Savings Card with Medicaid?

No. Federal anti-kickback statutes prohibit the use of manufacturer copay assistance cards (such as the Sanofi Lantus Valyou Savings Program) when the patient is enrolled in any federal health care program, including Medicaid, Medicare, CHIP, or TRICARE [15]. Using a manufacturer card to cover Medicaid cost-sharing is considered an illegal inducement.

The cash-pay alternative is approximately $35 per month through programs such as the Sanofi Insulins Valyou Savings Program for uninsured patients, or approximately $35 per vial through GoodRx or similar discount programs at participating pharmacies. These options are available only to patients who choose to pay out of pocket rather than use Medicaid for that prescription. Choosing to pay cash for a Medicaid-covered drug is the patient's right, but the plan will not reimburse cash payments.

For Medicaid enrollees who face a gap in coverage, state pharmaceutical assistance programs (SPAPs) and the Sanofi Patient Assistance Program (PAP), which provides free Lantus to qualifying uninsured or underinsured patients, are separate from copay cards and do not trigger the same legal concerns [15]. Income eligibility thresholds for PAPs vary by manufacturer.

Lantus and GLP-1 Agonists: A Note on Combination Coverage

Some patients with type 2 diabetes are prescribed both a basal insulin (Lantus) and a GLP-1 receptor agonist such as semaglutide (Ozempic) or liraglutide (Victoza). Coverage for the combination on Medicaid is not automatic. Fewer than half of state Medicaid programs cover GLP-1 receptor agonists for obesity alone; coverage for T2D is much broader but still subject to PA in most states [16].

A 2023 systematic review in Diabetes Care (covering 18 randomized trials, N=10,782) found that adding a GLP-1 agonist to basal insulin reduced HbA1c by an additional 1.0% to 1.5% and body weight by 2 to 5 kg compared with basal insulin alone [16]. Documenting this clinical rationale, together with the patient's T2D diagnosis code and inadequate glycemic control on basal insulin alone, strengthens a PA request for the combination.

iDegLira (Xultophy, insulin degludec plus liraglutide) and iGlarLixi (Soliqua, insulin glargine U-100 plus lixisenatide) are fixed-ratio combination products that pair a basal insulin with a GLP-1 agonist in a single injection. Soliqua contains the same insulin glargine molecule as Lantus. Medicaid coverage for these combination products varies considerably by state and typically requires separate PA from either component drug alone.